Evidence map›Paper›PMID 21071517›Full record

SynthesisClinical journal of the American Society of Nephrology : CJASN2011

Opioid and benzodiazepine use in end-stage renal disease: a systematic review.

Ahraaz Wyne, Raman Rai, Meaghan Cuerden, William F Clark, Rita S Suri

Registry-linked trialOpen access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04226443 (The Use of Midazolam and Remifentanil During Arteriovenous Fistula Placement Procedure and Monitored Anesthesia Care), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04226443 nacompletednot on this mapstarted 2012, after this paper: background citation

The Use of Midazolam and Remifentanil During Arteriovenous Fistula Placement Procedure and Monitored Anesthesia Care

TypeinterventionalSponsorKartal Kosuyolu Yuksek Ihtisas Education and Research HospitalRan2012 to 2016Enrolled99ConditionsSedative Adverse Reaction, Analgesic Adverse Reaction, Midazolam Adverse Reaction, Adverse Reaction to DrugArmsMidazolam intravenous injection, Remifentanil intravenous bolus dose
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Opioids in Hemodialysis Patients.Seminars in nephrology · 2021
    Review
  14. Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece.International journal of environmental research and public health · 2020
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ahraaz WyneUniversity of Western Ontario, London Kidney Clinical Research Unit, Room ELL-101 Victoria Hospital, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.
Raman Rai
Meaghan Cuerden
William F Clark
Rita S Suri
Western University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

BACKGROUND AND

objectivesChronic pain and psychiatric disorders are common in dialysis patients, but the extent to which opioids and benzodiazepines are used is unclear. We conducted a systematic review to determine the: (1) prevalence of opioid and benzodiazepine use among dialysis patients; (2) reasons for use; (3) effectiveness of symptom control; and (4) incidence of adverse events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two authors reviewed all relevant citations in MEDLINE/EMBASE/CINAHL/BIOSIS Previews/Cochrane and hand-searched bibliographies. Studies after 1990 reporting prevalence estimates for opioid and/or benzodiazepine use in ≥50 dialysis patients were included.

resultsWe identified 15 studies from 12 countries over 1995 to 2006. Sample size ranged from 75 to 12,782. Prevalence of opioid and benzodiazepine use was variable, ranging from 5 to 36% (95% CI, 4.1 to 45.5%; n=10) and 8 to 26% (95% CI, 7.1 to 27.3%; n=9), respectively. Prevalence was positively correlated with years on dialysis. Five studies reported on the same cohorts but gave different prevalence estimates. One study verified medication use through patient interviews. Reasons for use were reported in one study. Effectiveness of pain control varied from 17 to 38%, and 72 to 84% of patients with significant pain had no analgesia (n=2). No study rigorously examined for adverse events.

conclusionsThe prevalence of opioid and benzodiazepine use in dialysis patients is highly variable between centers. Further information is needed regarding the appropriateness of these prescriptions, adequacy of symptom control, and incidence of adverse effects in this population.

Indexed as

Analgesics, OpioidBenzodiazepinesCentral Nervous System DepressantsDrug UtilizationHumansKidney Failure, ChronicMental DisordersPainPain MeasurementRisk AssessmentRisk FactorsTreatment OutcomeAnalgesics, OpioidBenzodiazepinesCentral Nervous System Depressants

Identifiers

PMID21071517
PMCPMC3052223
OpenAlexW2100122075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.